06/10/2025
FOR IMMEDIATE RELEASE
Maxima Biotech Launches Global MedTech Partnership Platform, Showcasing Clinician-Driven Product Innovation at Medical Japan
TAIPEI, Taiwan – October 6, 2025 – Maxima Biotech Inc. (GISA: 7608), a Taiwanese company specializing in surgical device innovation, has announced the launch of its global partnership platform, offering turnkey solutions and CDMO services for MedTech commercialization. The company successfully validated its model at the recent Medical Japan trade show, where it showcased a next-generation surgical device designed through a rapid, clinician-driven innovation cycle that sets it apart from incumbent products.
The highlight was the debut of Maxima’s second-generation cordless ultrasonic scalpel, a device that exemplifies the company’s core value proposition to potential partners. Developed in just three years , the product is the result of an agile innovation loop driven by direct clinical feedback from over 5,000 surgeries in the Taiwanese market. This approach has led to specific, market-validated enhancements—such as an optimized Teflon pad and refined tip design —that directly address the unmet needs of surgeons, a process that challenges the slower innovation cycles of established global players.
"Our goal isn't just to create our own products; it's to offer a new, accelerated model for MedTech innovation as a service," said Dr. Tom Tang, CEO of Maxima Biotech. "Large corporations face challenges with R&D agility and supply chain complexity. Our platform provides a solution: a fast, flexible, and fully compliant pathway from clinical need to commercial product. We invite global leaders to partner with us to co-create the next generation of surgical tools."
Maxima Biotech's B2B platform offers two primary partnership models:
: For companies seeking to outsource development, Maxima provides a one-stop service that is more than just functional design. It offers comprehensive project management that adheres to strict international standards, including ISO 13485:2016 and QMS certifications.
: For partners aiming to establish or expand their own product lines, Maxima offers a complete turnkey solution. This service leverages Taiwan as a clinical validation site to fast-track commercialization. The solution encompasses the entire value chain, from design and regulatory certification to providing the go-to-market strategies necessary to compete effectively.
The strategic value of this model was immediately recognized at Medical Japan. Maxima engaged in high-level discussions with industry giants and received proactive inquiries from the investment arm of one of Japan’s top three financial groups, validating the market's demand for more agile innovation partners.
To further this strategic dialogue on a global stage, CEO Dr. Tom Tang will host a presentation at the upcoming MD&M West 2026 conference, inviting industry leaders for a face-to-face discussion on building resilient medical supply chains in the evolving geopolitical landscape.
About Maxima Biotech
Maxima Biotech (GISA: 7608) is a MedTech innovator offering an integrated commercialization platform for surgical devices. Guided by its mission to leverage Taiwan's tech prowess for world-class quality at a competitive cost, the company provides a complete value loop from market need to clinical validation and mass production. Led by a core team with over 15 years of average experience, Maxima helps global partners shorten development timelines, mitigate risks, and achieve market leadership.
